Neuronetics MT Cap Mental Health System Cleared

December 30, 2021

Malvern, Pa.-based Neuronetics has received the FDA’s 510(k) clearance for its MT Cap technology for use with the company’s NeuroStar advanced therapy for mental health.

The MT Cap provides a step-by-step map to reduce stages during the initial assessment for the NeuroStar system, which delivers transcranial magnetic stimulation treatment for major depressive disorder.

The company will begin marketing the technology in the U.S. in the coming weeks on a limited basis and is planning a national rollout by the end of March.

View today's stories